To increase the clinical applicability of NfL, future studies should explore the potential of plasma NfL for screening preclinical AD, predicting the risk of dementia onset among CH participants, and the rate of cognitive decline in participants with MCI. The gene discussed is NEFL; the disease is Alzheimer disease.